Please try another search
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Name | Age | Since | Title |
---|---|---|---|
David-Alexander C. Gros | 49 | 2020 | CEO & Non Independent Director |
Keith A. Katkin | 50 | 2015 | Independent Chairman of the Board |
Steven N. Perrin | 55 | 2020 | President, Chief Scientific Officer & Non Independent Director |
John S. McBride | 71 | 2017 | Independent Director |
Walter C. Ogier | 66 | 2020 | Independent Director |
Anne GM Schilder | - | 2018 | Member of Scientific Advisory Board |
Jan L. Hillson | 70 | 2021 | Independent Director |
Michael E. Pichichero | - | 2018 | Member of Scientific Advisory Board |
Paola Marchisio | - | 2018 | Member of Scientific Advisory Board |
June H. Lee | 57 | 2020 | Independent Director |
Tal Marom | - | 2018 | Member of Scientific Advisory Board |
Hamid Djalilian | - | 2018 | Member of Scientific Advisory Board |
Seth Pranksy | - | 2018 | Member of Scientific Advisory Board |
Allan Douglas Kirk | 62 | 2023 | Independent Director |
James A. Robinson | 54 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review